Nurami Medical, a medical device R&D company, which is developing a groundbreaking technology that facilitates post-surgical healing of soft tissue healing, has announced that it
Nurami Medical was awarded the Seal of Excellence under the Horizon 2020’s SME Instrument of the European Commission. Following evaluation by an international panel of
Nurami has announced the initiation of NEOART clinical study to test its Dural repair patch – ArtiFascia®. Multiple leading EU medical centers participate in the
We are proud to advise that our first patent has been granted in USA. This patent has previously been granted in China too.
Dr. Brem, the Harvey Cushing Professor of Neurosurgery at The Johns Hopkins University, Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief joined Nurami Medical’s scientific
Nora Nseir, Nurami Medical co-founder and CTO was selected among the top 4 finalists at the EU Woman Innovator in 2019.
ArtiFasciaTM First-in-Human clinical study has been successfully completed 6 patients were implanted with ArtiFasciaTM with a 6 month follow-up period No device related adverse events